AA
FULC icon

ALPS Advisors’s Fulcrum Therapeutics FULC Stock Holding History

ALPS Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-123,009
Closed -$439K – 1008
2024
Q3 		$439K Buy
123,009
+74,530
+154% +$553K ﹤0.01% 628
2024
Q2 		$301K Buy
48,479
+4,797
+11% +$36.3K ﹤0.01% 847
2024
Q1 		$412K Buy
43,682
+3,828
+10% +$34.2K ﹤0.01% 620
2023
Q4 		$269K Buy
+39,854
New +$177K ﹤0.01% 909
2023
Q2 		– Sell
-40,692
Closed -$116K – 1014
2023
Q1 		$116K Buy
40,692
+5,334
+15% +$47.8K ﹤0.01% 997
2022
Q4 		$257K Buy
+35,358
New +$231K ﹤0.01% 951

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ALPS Advisors's FULC Position: Q4 2024 in Review

ALPS Advisors sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 123,009 shares — an estimated $439K sold.

ALPS Advisors first reported a position in FULC in Q4 2022 and held it in 6 quarters. The position peaked at $439K in Q3 2024. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • ALPS Advisors reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • ALPS Advisors sold 123,009 Fulcrum Therapeutics shares in Q4 2024, an estimated $439K.
  • ALPS Advisors first reported a position in Fulcrum Therapeutics in Q4 2022 and held it in 6 quarters.
  • ALPS Advisors's Fulcrum Therapeutics position peaked at $439K in Q3 2024.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on ALPS Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.